Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 413-920-6 | CAS number: 88949-33-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1992-1993
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Referenceopen allclose all
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 993
- Report date:
- 1993
- Reference Type:
- other: Amendment to study report
- Title:
- Unnamed
- Year:
- 1 995
- Report date:
- 1995
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- May 12, 1981
- Deviations:
- yes
- Remarks:
- No functional observations
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- -
- EC Number:
- 413-920-6
- EC Name:
- -
- Cas Number:
- 88949-33-1
- Molecular formula:
- C30 H20 N2 O2
- IUPAC Name:
- 3,6-bis({[1,1'-biphenyl]-4-yl})-1H,2H,4H,5H-pyrrolo[3,4-c]pyrrole-1,4-dione
- Test material form:
- solid: particulate/powder
Constituent 1
- Specific details on test material used for the study:
- - Substance type: Organic
- Physical state: Solid
- Lot/batch No.: Z-2281/1,2,4,5
- Expiration date of the lot/batch: April 01, 1997
- Storage condition of test material: at room temperature in the dark
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: BRL Ltd., Basel, Switzerland
- Age at study initiation: Approximately 6 weeks
- Weight at study initiation: males (mean): 170g (males), 140g (females)
- Housing: 5 animals per cage
- Diet (e.g. ad libitum): Free access to standard pelleted laboratory animal diet
- Water (e.g. ad libitum): Free access to tap water
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3
- Humidity (%): 30-70
- Photoperiod (hrs dark / hrs light): 12 hours/12 hours
In-Life-phase: 1993-02-09 to 1993-04-07
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- polyethylene glycol
- Details on oral exposure:
- - PREPARATION OF DOSING SOLUTIONS: Formulations (w/w) were prepared daily within 4 hours prior to dosing, and were homogenised to visually acceptable levels.
- DOSE VOLUME: 10 ml/kg body weight. Actual dose volumes were calculated weekly according to the latest body weight.
- RECOVERY: for 14 days - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Test substance formulations in polyethylene glycol formed homogeneous suspensions. Analysis of the accuracy of dose preparations revealed values within the range of 3% to 4% of nominal, which was considered to represent an acceptable level of accuracy for formulations of this type.
- Duration of treatment / exposure:
- Treatment for 28 days, 7 days per week, two weeks of treatment-free recovery for satellite group.
- Frequency of treatment:
- Once daily (7 days per week)
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (actual dose received)
- Remarks:
- Basis: actual ingested
- Dose / conc.:
- 50 mg/kg bw/day (actual dose received)
- Remarks:
- Basis: actual ingested
- Dose / conc.:
- 200 mg/kg bw/day (actual dose received)
- Remarks:
- Basis: actual ingested
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- Remarks:
- Basis: actual ingested
- No. of animals per sex per dose:
- 5 animals
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Based on the results of a 5-day range finding study, the dose levels for the 28-day toxicity study were selected to be 0, 50, 200 and 1000 mg/kg/day
- Positive control:
- no
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily
- Cage side observations: Mortality/Viability
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: At least once daily
BODY WEIGHT: Yes
- Time schedule for examinations: Weekly and on the day preceding termination, prior to overnight fasting.
FOOD CONSUMPTION: Yes
- Time schedule: Weekly
WATER CONSUMPTION: Yes
- Time schedule for examinations: Subjective appraisal was maintained during the study, but no quantitative investigation introduced as no effect was suspected
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: week 4; Since no treatment-related ophthalmoscopic effects were noted in week 4, no ophthalmoscopic examination was performed in week 6
- Dose groups that were examined: all groups
HAEMATOLOGY: Yes
- Time schedule for collection of blood: prior to scheduled post mortem examination
- Anaesthetic used for blood collection: Yes, ether
- Animals fasted: Yes, overnight (with a maximum of 20 hours)
- Parameters checked: Erythrocytes count, Haemoglobin, Haematocrit, Mean corpuscular volume, Mean corpuscular haemoglobin, Mean corpuscular haemoglobin concentration, Platelets count, Red cell distribution width, Total leucocytes count, Differential leucocyte count (Neutrophils, Eosinophils, Basophils, Lymphocytes, Monocytes); Prothrombin time, Partial thromboplastin time
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: prior to scheduled post mortem examination
- Animals fasted: Yes, overnight (with a maximum of 20 hours)
- Parameters checked: Alanine aminotransferase, Alkaline phosphatase, Aspartate aminotransferase, Gamma-glutamyl transferase, Bilirubin (total), Chloride, Cholesterol (total), Creatinine, Glucose, Phosphorus, Protein (total), Protein (albumin, globulin, Albumin Globulin ratio), Triglycerides, Urea, Calcium, Potassium, Sodium - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes, of - Adrenal glands, Aorta, Brain (representative regions, including cerebrum, cerebellum and pons), Caecum (Cervix), (Clitoral gland), Colon, Duodenum, Epididymides, (Eyes with optic nerve and Harderian gland), (Female mammary gland area), (Femur including joint), Heart, Ileum, Jejunum, Kidneys, (Larynx), (Lacrimal gland, exorbital), Liver, Lung (infused with formalin), Lymph nodes (mandibular, mesenteric), (Nasopharynx), Oesophagus, Ovaries, Pancreas, Peyer's patches (jejunum, ileum) if detectable, Pituitary gland, (Preputial gland), Prostate gland, Rectum, (Salivary glands - mandibular, sublingual), Sciatic nerve, (Seminal vesicles), (Skeletal muscle), (Skin), Spinal cord (cervical, midthoracic, lumbar), Spleen, Sternum with bone marrow, Stomach, Testes, Thymus, Thyroid including parathyroid, (Tongue), Trachea, Urinary bladder, Uterus, (Vagina), all gross lesions
- Organ weights: Adrenal glands, Kidneys, Ovaries, Testes, Brain, Heart, Liver, Spleen.
HISTOPATHOLOGY: Yes, Slides of adrenals, heart, kidneys, liver, spleen, stomach and testes, collected at termination from all animals of the control group and the high dose group, as well as from all gross lesions of all animals were examined by a pathologist. All abnormalities were described and included in the report. - Statistics:
- The following statistical methods were used to analyse the data:
- If the variables could be assumed to follow a normal distribution, the Dunnett-test (many-to one t-test) based on a pooled variance estimate was applied for the comparison of the treated groups and the control groups for each sex.
- The Steel-test (many-to-one rank test) was applied when the data could not be assumed to follow a normal distribution.
- The exact Fisher-test was applied to frequency data
All tests were two-sided and in all cases p < 0.05 was accepted as the lowest level of significance.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no clinical signs of toxicity during the study period that were considered to be related to treatment. Red appearance of tissues and faeces was observed in all animals of the treatment groups during the 4 weeks of oral treatment. The red staining of tissues were attributed to contact with the red discoloured faeces. Among males receiving 50 mg/kg/day (Group 2), only the tail was noted to be red and among animals receiving 200 or 1000 mg/kg/day (Groups 3 and 4, respectively), the anus region or other parts of the whole body were also affected. Since the test substance is a red pigment, these findings were attributed to the physico-chemical properties of the test substance.
- Mortality:
- no mortality observed
- Description (incidence):
- No mortality occurred during the study period.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Body weights and body weight gain of treated animals were considered to have been unaffected by treatment with the test substance.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- There were no differences in food consumption before or after allowance for body weight between treated and control animals.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- There were no ophthalmoscopic findings in week 4.
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- Haematological parameters of treated rats were considered not to have been affected by treatment.
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- Clinical chemistry parameters of treated rats were considered not to have been affected by treatment.
- Endocrine findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- There were no behavioural changes during the study period that were considered to be related to treatment.
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Organ weights of animals receiving 50, 200 or 1000 mg/kg/day (Groups 2, 3 and 4) were considered to be similar as organ weights of control animals after 4 weeks of treatment and the subsequent recovery period. The statistically significant increase of the relative kidney weight (relative to the body weight) of males receiving 1000 mg/kg/day (Group 4) at week 4, when compared to the corresponding control males, was considered to have arisen by chance, as there were no corroborative findings noted in the opposite sex or in other toxicological parameters measured.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- Macroscopic observations at necropsy did not reveal any alterations that were considered to have arisen as a result of treatment.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- There were no microscopic findings recorded which could be attributed to treatment with the test substance.
- Histopathological findings: neoplastic:
- no effects observed
- Description (incidence and severity):
- There were no microscopic findings recorded which could be attributed to treatment with the test substance.
Effect levels
- Dose descriptor:
- NOEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No effects observed up to and including the highest dose tested.
Target system / organ toxicity
- Critical effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- Under the experimental conditions of the study, the No Observed Effect Level (NOEL) was considered to be 1000 mg/kg bw/day.
- Executive summary:
The subacute oral toxicity of the test substance was investigated in a GLP conform study according to OECD guideline 407. The test substance was administered daily for 28 consecutive days by oral gavage to male and female Wistar rats, followed by a 14-day recovery period. The dose levels were selected to be 0, 50, 200 and 1000 mg/kg/day based on the results of a 5-day range finding study. One control group and the treatment groups consisted of 5 males and 5 females each. An extra 5 animals per sex in the control and high dose group were allowed for recovery. Clinical signs were evaluated daily, body weight and food consumption weekly, ophthalmoscopy at week 4, clinical pathology, macroscopy, organ weights and histopathology on a selection of tissues at termination. No treatment related findings were observed. The study design did not include a functional observation battery. This is considered be a non-critical deviation as the substance did not cause any adverse effects and toxicokinetic data on a related pigment shows absence of systemic availability after ingestion. From the results of the study, a definitive No Observed Adverse Effect Level (NOAEL) and No Observed Effect Level (NOEL) of 1000 mg/kg bw/day was established.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.